January 8, 2018: Clinical Results to Be Presented at AUA Annual Meeting
Dr. Suzette Sutherland, University of Washington, Seattle has been invited to make a podium presentation of the FemPulse clinical study results at the American Urology Association (AUA) annual meeting to be held in San Francisco on May 18 – 21, 2018. This invitation reflects well on the clinical and scientific merit of the FemPulse study, […]
December 31, 2017: FemPulse Corporation Formed
FemPulse announced completion of a conversion from its original legal structure, a Limited Liability Company, to a “C” corporation to be known as FemPulse Corporation. This conversion positions the company for accelerating growth and development of its commercial operations. All LLC members converted their member interests into shares in FemPulse Corporation.
September 21, 2017: FemPulse Invited to Present at the Medical Alley Innovation Summit
Don Deyo, CEO, will be presenting on the status and direction for the Company at the Medical Alley Innovation Summit sponsored in conjunction with The MedTech Strategist. The conference brings the proven format of annual Dublin Innovation Summit to the epicenter of medtech innovation, Minneapolis-St. Paul, MN. The Company is honored to have the opportunity […]
August 22, 2017: Fifth FemPulse Patent Granted
The US Patent Office has granted the fifth FemPulse patent (#9,737,707). This new patent covers use of capacitor technology for both vaginally inserted and implantable nerve stimulation. The company’s IP portfolio continues to grow, with numerous additional claims filed.
April 18, 2017: FemPulse Completes Clinical Study Enrollment
The 15-subject enrollment level approved for the company-sponsored clinical study has been met. The final subject is expected to complete the multi-day protocol in approximately six weeks. The enrollment limit was reached in just 9 weeks, providing another indication of the tremendous number of women afflicted with OAB and the urgent need for new and […]
February 14, 2017: FemPulse Enrolls First Clinical Study Subject
The Company is pleased to announce the first enrollment in its clinical evaluation to assess fit, comfort, patient placement and safety of the FemPulse therapy, as well as the potential for improvement in symptoms associated with OAB. The subject, a 69 year old female, was afflicted with urgency and urinary urge incontinence.
February 13, 2017: FemPulse Establishes Highly-Experienced Board of Directors
FemPulse LLC announces the formation of a formal board of directors (BoD) to help guide the strategic direction for the fast-moving organization. Members of the BoD includes the co-founders, Alexandra Haessler, MD and Peter Fredericks, MBA/PhD and Donald Deyo, Jeff Korn, Darrin Uecker and Flip Gianos. Don and Jeff serve as CEO and Corporate Counsel […]
December 2, 2016: FemPulse Expands Clinical Study to Additional Center
Metro Urology, St. Paul, MN has received institutional review board approval to become the second center in the clinical study sponsored by the Company. Approval of Metro Urology by the Western IRB (WIRB) allows for the evaluation of this novel therapy in private practice, as well as in the previously approved academic institution. The Company […]
September 7, 2016: FemPulse Receives Institutional Review Board Approval
The Company announced today approval of the First-in-Human (FIH) clinical study of its novel, wearable neuromodulation platform for treating overactive bladder (OAB) in females. The Western IRB (WIRB) approved participation of up to 15 subjects in a study assessing fit, patient placement and safety of the FemPulse device, as well as potential for improvement in […]
July 7, 2016: Fourth FemPulse Patent Granted
The US Patent Office has granted the fourth FemPulse patent (#9,381,351). This broad patent grants claims regarding implantation and stimulation of nerves within the peritoneal cavity. With its extensive patent portfolio, FemPulse is uniquely positioned to advance the field of wearable neuromodulation therapy for Overactive Bladder.
